HUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Update

HUTCHMED (China) Limited (NASDAQ:HCM) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 467,900 shares, a decline of 8.1% from the November 30th total of 509,300 shares. Based on an average daily volume of 95,100 shares, the days-to-cover ratio is presently 4.9 days.

HUTCHMED Stock Up 0.3 %

Shares of NASDAQ HCM traded up $0.05 during mid-day trading on Wednesday, hitting $14.41. 39,395 shares of the stock traded hands, compared to its average volume of 114,476. The stock has a fifty day moving average price of $17.05 and a 200-day moving average price of $17.92. HUTCHMED has a 52 week low of $11.93 and a 52 week high of $21.92. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Trading of HUTCHMED

Hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new stake in shares of HUTCHMED in the 3rd quarter worth approximately $35,000. Blue Trust Inc. boosted its holdings in HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after acquiring an additional 3,057 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after acquiring an additional 2,321 shares during the last quarter. Rhumbline Advisers grew its stake in shares of HUTCHMED by 8.1% in the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after acquiring an additional 564 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of HUTCHMED during the second quarter valued at $213,000. Institutional investors own 8.82% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.